Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M72/AS01E TB Vaccine in Virally Suppressed HIV Participants
NCT04556981Phase 2Completed
- Sponsor
- Gates Medical Research Institute
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing M72/AS01E vaccine with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Adverse Events (AEs) Through 7 Days Post Dose 1, Number of Participants With Solicited AEs Through 7 Days Post Dose 2 and 3 more. Started Nov 2020; status: completed.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04556981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556981.